Application of Yiganle tablets in preparing medicine for inhibiting cell proliferation of malignant pleural mesothelioma cell SMC-1

A technology of SMC-1 and cell proliferation, applied in anti-tumor drugs, drug combinations, pharmaceutical formulations, etc., can solve the problems of backwardness, many impurities, and inconvenience to take.

Inactive Publication Date: 2016-06-22
JINAN XINSHIDAI MEDICINE SCI & TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In the prior art, there is no report on the application of Yiganle tablets in the preparation of drugs to inhibit the proliferation of human malignant pleural mesothelioma cells SMC-1 cells, and there is no report on the use of supercritical extraction in the extraction and preparation of Yiganl

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Take 200g of chicken vine, 160g of Polygonum cuspidatum, 200g of verbena, 200g of June snow, 200g of Malan grass, 200g of Mao berry, 170g of auspicious grass, 100g of Gonggong wood and 70g of cold water flower, and add it to CO 2 In the supercritical extractor, ethanol is used as an entrainer, and the volume percentage of the entrainer to the total extraction solvent is 5%, the extraction pressure is 25MPa, the temperature is 40°C, and the CO 2 The flow rate is 2ml / g crude drug·min, the extraction time is 750min, and the supercritical extract is obtained. The supercritical extract is added to starch and 70% ethanol to make granules, dried, and pressed into tablets to make 200 tablets, each weighing 0.30g.

[0025] After testing, the content of emodin in the finished product is 1.85mg / tablet.

Embodiment 2

[0027] Take 200g of chicken vine, 160g of Polygonum cuspidatum, 200g of verbena, 200g of June snow, 200g of Malan grass, 200g of Mao berry, 170g of auspicious grass, 100g of Gonggong wood and 70g of cold water flower, and add it to CO 2 In a supercritical extractor, ethanol is used as an entrainer, and the entrainer accounts for 4% by volume of the total extraction solvent. The extraction pressure is 15MPa, the temperature is 30°C, and the CO 2 The flow rate is 1ml / g crude drug·min, the extraction time is 900min, and the supercritical extract is obtained. The supercritical extract is added to starch and 70% ethanol to make granules, dried, and pressed into tablets to make 200 tablets, each weighing 0.30g.

[0028] After testing, the content of emodin in the finished product is 1.21mg / tablet.

Embodiment 3

[0030] Take 200g of chicken vine, 160g of Polygonum cuspidatum, 200g of verbena, 200g of June snow, 200g of Malan grass, 200g of Mao berry, 170g of auspicious grass, 100g of Gonggong wood and 70g of cold water flower, and add it to CO 2 In the supercritical extractor, ethanol is used as an entrainer, and the volume percentage of the entrainer in the total extraction solvent is 6%, the extraction pressure is 30MPa, the temperature is 60°C, and the CO 2 The flow rate is 3ml / g crude drug·min, the extraction time is 800min, and the supercritical extract is obtained. The supercritical extract is added to starch and 70% ethanol to make granules, dried, and pressed into tablets to make 200 tablets, each weighing 0.30g.

[0031] After testing, the content of emodin in the finished product is 0.95mg / tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of traditional Chinese medicines and particularly relates to an application of Yiganle tablets in preparing a medicine for inhibiting the cell proliferation of the malignant pleural mesothelioma cell SMC-1 and a preparation method of Yiganle tablets. The Yiganle tablets are prepared from the active pharmaceutical ingredients including 200g of paederia scandens, 160g of polygonum cuspidatum, 200g of verveine officinale, 200g of serissa japonica, 200g of herba kalimeridis, 200g of rubus parvifolius, 170g of pink reineckea herb, 100g of caulis mahoniae and 70g of pilea notata by supercritical extraction, and the content of emodin is greatly increased.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicines, and specifically relates to the application of Yiganle tablets in the preparation of drugs for inhibiting the proliferation of malignant pleural mesothelioma cells SMC-1 cells and the preparation method of Yiganle tablets. Background technique [0002] The standard number of Yiganle Granules is WS-10148 (ZD-0148)-2002, which is recorded in the Hepatobiliary Subvolume of the National Compilation of Chinese Patent Medicine Standards. It is made from 200g of Gallus vine, 160g of Polygonum cuspidatum, 200g of Verbena, 200g of June Snow, 200g of Malancao, 200g of Maoberry, 170g of Auspicious Grass, 100g of Gongluomu, and 70g of Lengshuihua. effect. For acute and chronic hepatitis B caused by liver and gallbladder damp heat. [0003] In the prior art, there is no report on the application of Yiganle tablets in the preparation of drugs to inhibit the proliferation of human malign...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/896A61P35/00
CPCA61K36/896A61K9/2059A61K36/185A61K36/28A61K36/282A61K36/29A61K36/41A61K36/47A61K36/704A61K36/73A61K36/74A61K36/85A61K2236/37A61K2300/00
Inventor 不公告发明人
Owner JINAN XINSHIDAI MEDICINE SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products